(Q42539073)

1 November 2017

title

Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine (English)

1 reference

primary pulmonary hypertension

1 November 2017

main subject

1 reference

Ricciardi MJ

1

1 reference

1 November 2017

Knight BP

series ordinal

2

1 reference

1 November 2017

Martinez FJ

series ordinal

3

1 reference

1 November 2017

Rubenfire M

series ordinal

4

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

Journal of the American College of Cardiology

1 November 2017

published in

1 reference

1 November 2017

volume

32

1 reference

1 November 2017

issue

4

1 reference

1 November 2017

page(s)

1068-1073

1 reference

Primary pulmonary hypertension

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

The cardiac effects of adenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Adenosine as a vasodilator in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Adenosine and selective reduction of pulmonary vascular resistance in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Comparison of the effects of adenosine and nifedipine in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Primary pulmonary hypertension. A national prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Inhaled nitric oxide for the adult respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

The interaction between nitrogen oxides and hemoglobin and endothelium-derived relaxing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

Caution with use of inhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900361-1

7 January 2021

10.1016/S0735-1097(98)00361-1

Identifiers

DOI

1 reference

1 November 2017

1 reference